Cancer Epidemiology Biomarkers Prevention a Publication of the American Association For Cancer Research Cosponsored By the American Society of Preventive Oncology, Nov 1, 2002
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Jan 5, 2016
Comorbid medical conditions are common among breast cancer survivors, contribute to poorer long-t... more Comorbid medical conditions are common among breast cancer survivors, contribute to poorer long-term survival and increased overall mortality, and may be ameliorated by weight loss. This secondary analysis evaluated the impact of a weight loss intervention on comorbid medical conditions immediately following an intervention (12 months) and 1-year postintervention (24 months) using data from the Exercise and Nutrition to Enhance Recovery and Good health for You (ENERGY) trial-a phase III trial which was aimed at and successfully promoted weight loss. ENERGY randomized 692 overweight/obese women who had completed treatment for early stage breast cancer to either a 1-year group-based behavioral intervention designed to achieve and maintain weight loss or to a less intensive control intervention. Minimal support was provided postintervention. New medical conditions, medical conditions in which non-cancer medications were prescribed, hospitalizations, and emergency room visits, were comp...
Cancer Epidemiology Biomarkers Prevention a Publication of the American Association For Cancer Research Cosponsored By the American Society of Preventive Oncology, Jun 1, 2004
... 4Department of Maternal & Child Health, Harvard School of Public Health, Boston, ... more ... 4Department of Maternal & Child Health, Harvard School of Public Health, Boston, Massachusetts. 5Correspondence should be directed to Robin E. Blum, Charming Laboratory, 181 Longwood Avenue, Boston, Massachusetts 02115; e-mail: [email protected] ...
To examine the association between postmenopausal hormone use and cholecystectomy. A prospective ... more To examine the association between postmenopausal hormone use and cholecystectomy. A prospective cohort study was performed, with follow-up every 2 years. Participants were 54,845 postmenopausal United States nurses, who reported both hormone use and cholecystectomy on mailed questionnaires. Cholecystectomy was reported by 1750 women during 8 years of follow-up. After adjusting for confounding factors, women currently using postmenopausal hormones were at an increased risk of cholecystectomy (relative risk [RR] 2.1, 95% confidence interval [CI] 1.9-2.4) compared to never-users. For current users, the risk of cholecystectomy increased with increasing duration of hormone use (RR 2.6, 95% CI 2.2-3.1 for 10 years or more) and higher doses of estrogen (RR 2.4, 95% CI 2.0-2.9 for users of 1.25 mg or more). Although the risk for past hormone users decreased substantially in women who had discontinued use 1-2.9 years ago (RR 1.6, 95% CI 1.2-2.0), a small risk persisted for women who had stopped taking hormones 5 or more years previously (RR 1.3, 95% CI 1.1-1.6). However, after controlling for time since last use, duration of past use had little or no effect on the risk of cholecystectomy (RR 1.4 and RR 1.7 for past users of less than 2 years and 10 or more years' duration, respectively). Women using postmenopausal hormones are at an increased risk of cholecystectomy. Women and their physicians should consider the spectrum of risks and benefits when deciding whether to take hormones.
The association between obesity and multiple myeloma (MM) risk may be partly attributed to reduce... more The association between obesity and multiple myeloma (MM) risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate MM risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 MM cases and 1,246 individually matched controls from seven cohorts participating in the MM Cohort Consortium. Analysis of circulating analyte levels measured by enzyme-linked immunosorbent assays revealed that higher total adiponectin levels were associated with reduced MM risk overall (highest quartile vs. lowest: odds ratio [OR]=0.64, 95% confidence interval [CI]=0.47-0.85; Ptrend = 0.001). This association was apparent among cases diagnosed six or more years after blood collection (OR=0.60, CI=0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR=0.59 and 0.66, respectively). Interes...
In a prospective cohort study of 1271 Massachusetts residents 66 years of age or older, we examin... more In a prospective cohort study of 1271 Massachusetts residents 66 years of age or older, we examined the association between consumption of carotene-containing vegetables and subsequent five year mortality. Dietary information was obtained by food frequency questionnaire in 1976. The relative risk of cancer mortality was examined within quintiles of green and yellow vegetable score (calculated from intake of carrots or squash, tomatoes, salads or leafy vegetables, dried fruits, fresh strawberries or fresh melon, and broccoli or brussel sprouts). After controlling for age and smoking behavior, those in the highest quintile of intake of these carotene-containing vegetables had a risk of cancer mortality which was 0.3 (95% confidence limits 0.10-0.96) that of those in the lowest quintile. The trend of decreased cancer risk with increasing intake of carotene containing vegetables was significant (p = .026). This relationship is consistent with the hypothesis that carotene may act as an inhibitor of carcinogenesis.
ABSTRACT Purpose: Multiple myeloma (MM) is the second most common hematologic malignancy in the U... more ABSTRACT Purpose: Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and is preceded by monoclonal gammopathy of undetermined significance (MGUS). We aimed to investigate the association between obesity and the progression from MGUS to MM. Methods: Patients with MGUS diagnosed between October 1, 1999 and December 31, 2009 were identified in the U.S. Veterans Health Administration (VHA) database based on the Ninth Revision of the International Classification of Diseases (ICD-9) code 273.1. Unique identifiers of patients were used to link data from the inpatient and outpatient data to the pharmacy data on MM treatment. MM incidence was determined by at least two occurrences of ICD-9 code 203.0 and treatment at any VHA facility within six months of diagnosis. Moreover, two investigators reviewed patient-level clinical data to verify actual diagnosis and date of diagnosis. Interval-censored survival analysis was used, because the time when MM occurs is not directly observed but is known to take place between MGUS and MM diagnoses. Nonparametric maximum likelihood estimator of the survival curves were generated using the expectation-maximization iterative convex minorant algorithm. Multivariate survival analysis, controlling for body mass index (BMI), gender, race, comorbidities, level of creatinine, marital status, and income level, was conducted by parametric accelerated failure time interval-censored analysis with Weibull-modeled survival time. BMI was categorized into normal-weight: 18.5≤BMI<25, overweight: 25≤BMI<30, and obese: BMI>30. Results: Our sample comprised 9,430 MGUS patients. Among them, 509 patients (5.3%) progressed to MM. Survival curves show the patterns of transformation from MGUS to MM by BMI groups (Figure). In the multivariate analysis, overweight (HR: 1.48; 95% CI: 1.17-1.88) and obese (HR: 1.70; 95% CI: 1.32-2.19) patients were associated with an increased risk of transformation from MGUS to MM. Black race had a higher risk of progression (HR: 1.92; 95% CI: 1.58-2.35). Patients with higher creatinine level (HR: 0.74; 95% CI: 0.59-0.93) and higher Charlson comorbidity index (HR: 0.94; 95% CI: 0.92-0.98) were less likely to develop MM. Conclusions: This study provides evidence suggesting that overweight or obesity was associated with an elevated risk of transformation from MGUS to MM. As obesity is the only modifiable risk factor for this transformation, we suggest that clinical practice recommend weight loss to people with higher risks of developing MGUS or MM.
Cancer Epidemiology Biomarkers Prevention a Publication of the American Association For Cancer Research Cosponsored By the American Society of Preventive Oncology, Nov 1, 2002
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Jan 5, 2016
Comorbid medical conditions are common among breast cancer survivors, contribute to poorer long-t... more Comorbid medical conditions are common among breast cancer survivors, contribute to poorer long-term survival and increased overall mortality, and may be ameliorated by weight loss. This secondary analysis evaluated the impact of a weight loss intervention on comorbid medical conditions immediately following an intervention (12 months) and 1-year postintervention (24 months) using data from the Exercise and Nutrition to Enhance Recovery and Good health for You (ENERGY) trial-a phase III trial which was aimed at and successfully promoted weight loss. ENERGY randomized 692 overweight/obese women who had completed treatment for early stage breast cancer to either a 1-year group-based behavioral intervention designed to achieve and maintain weight loss or to a less intensive control intervention. Minimal support was provided postintervention. New medical conditions, medical conditions in which non-cancer medications were prescribed, hospitalizations, and emergency room visits, were comp...
Cancer Epidemiology Biomarkers Prevention a Publication of the American Association For Cancer Research Cosponsored By the American Society of Preventive Oncology, Jun 1, 2004
... 4Department of Maternal & Child Health, Harvard School of Public Health, Boston, ... more ... 4Department of Maternal & Child Health, Harvard School of Public Health, Boston, Massachusetts. 5Correspondence should be directed to Robin E. Blum, Charming Laboratory, 181 Longwood Avenue, Boston, Massachusetts 02115; e-mail: [email protected] ...
To examine the association between postmenopausal hormone use and cholecystectomy. A prospective ... more To examine the association between postmenopausal hormone use and cholecystectomy. A prospective cohort study was performed, with follow-up every 2 years. Participants were 54,845 postmenopausal United States nurses, who reported both hormone use and cholecystectomy on mailed questionnaires. Cholecystectomy was reported by 1750 women during 8 years of follow-up. After adjusting for confounding factors, women currently using postmenopausal hormones were at an increased risk of cholecystectomy (relative risk [RR] 2.1, 95% confidence interval [CI] 1.9-2.4) compared to never-users. For current users, the risk of cholecystectomy increased with increasing duration of hormone use (RR 2.6, 95% CI 2.2-3.1 for 10 years or more) and higher doses of estrogen (RR 2.4, 95% CI 2.0-2.9 for users of 1.25 mg or more). Although the risk for past hormone users decreased substantially in women who had discontinued use 1-2.9 years ago (RR 1.6, 95% CI 1.2-2.0), a small risk persisted for women who had stopped taking hormones 5 or more years previously (RR 1.3, 95% CI 1.1-1.6). However, after controlling for time since last use, duration of past use had little or no effect on the risk of cholecystectomy (RR 1.4 and RR 1.7 for past users of less than 2 years and 10 or more years' duration, respectively). Women using postmenopausal hormones are at an increased risk of cholecystectomy. Women and their physicians should consider the spectrum of risks and benefits when deciding whether to take hormones.
The association between obesity and multiple myeloma (MM) risk may be partly attributed to reduce... more The association between obesity and multiple myeloma (MM) risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate MM risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 MM cases and 1,246 individually matched controls from seven cohorts participating in the MM Cohort Consortium. Analysis of circulating analyte levels measured by enzyme-linked immunosorbent assays revealed that higher total adiponectin levels were associated with reduced MM risk overall (highest quartile vs. lowest: odds ratio [OR]=0.64, 95% confidence interval [CI]=0.47-0.85; Ptrend = 0.001). This association was apparent among cases diagnosed six or more years after blood collection (OR=0.60, CI=0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR=0.59 and 0.66, respectively). Interes...
In a prospective cohort study of 1271 Massachusetts residents 66 years of age or older, we examin... more In a prospective cohort study of 1271 Massachusetts residents 66 years of age or older, we examined the association between consumption of carotene-containing vegetables and subsequent five year mortality. Dietary information was obtained by food frequency questionnaire in 1976. The relative risk of cancer mortality was examined within quintiles of green and yellow vegetable score (calculated from intake of carrots or squash, tomatoes, salads or leafy vegetables, dried fruits, fresh strawberries or fresh melon, and broccoli or brussel sprouts). After controlling for age and smoking behavior, those in the highest quintile of intake of these carotene-containing vegetables had a risk of cancer mortality which was 0.3 (95% confidence limits 0.10-0.96) that of those in the lowest quintile. The trend of decreased cancer risk with increasing intake of carotene containing vegetables was significant (p = .026). This relationship is consistent with the hypothesis that carotene may act as an inhibitor of carcinogenesis.
ABSTRACT Purpose: Multiple myeloma (MM) is the second most common hematologic malignancy in the U... more ABSTRACT Purpose: Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and is preceded by monoclonal gammopathy of undetermined significance (MGUS). We aimed to investigate the association between obesity and the progression from MGUS to MM. Methods: Patients with MGUS diagnosed between October 1, 1999 and December 31, 2009 were identified in the U.S. Veterans Health Administration (VHA) database based on the Ninth Revision of the International Classification of Diseases (ICD-9) code 273.1. Unique identifiers of patients were used to link data from the inpatient and outpatient data to the pharmacy data on MM treatment. MM incidence was determined by at least two occurrences of ICD-9 code 203.0 and treatment at any VHA facility within six months of diagnosis. Moreover, two investigators reviewed patient-level clinical data to verify actual diagnosis and date of diagnosis. Interval-censored survival analysis was used, because the time when MM occurs is not directly observed but is known to take place between MGUS and MM diagnoses. Nonparametric maximum likelihood estimator of the survival curves were generated using the expectation-maximization iterative convex minorant algorithm. Multivariate survival analysis, controlling for body mass index (BMI), gender, race, comorbidities, level of creatinine, marital status, and income level, was conducted by parametric accelerated failure time interval-censored analysis with Weibull-modeled survival time. BMI was categorized into normal-weight: 18.5≤BMI<25, overweight: 25≤BMI<30, and obese: BMI>30. Results: Our sample comprised 9,430 MGUS patients. Among them, 509 patients (5.3%) progressed to MM. Survival curves show the patterns of transformation from MGUS to MM by BMI groups (Figure). In the multivariate analysis, overweight (HR: 1.48; 95% CI: 1.17-1.88) and obese (HR: 1.70; 95% CI: 1.32-2.19) patients were associated with an increased risk of transformation from MGUS to MM. Black race had a higher risk of progression (HR: 1.92; 95% CI: 1.58-2.35). Patients with higher creatinine level (HR: 0.74; 95% CI: 0.59-0.93) and higher Charlson comorbidity index (HR: 0.94; 95% CI: 0.92-0.98) were less likely to develop MM. Conclusions: This study provides evidence suggesting that overweight or obesity was associated with an elevated risk of transformation from MGUS to MM. As obesity is the only modifiable risk factor for this transformation, we suggest that clinical practice recommend weight loss to people with higher risks of developing MGUS or MM.
Uploads
Papers by Graham Colditz